IMDX insider disclosures
Explore public SEC filings by reporting investor and stock. Filings can appear after the activity they describe. Joint filing lines link to each reporting owner’s profile.
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source | Follow |
|---|---|---|---|---|---|---|---|
| SMITH PATRICK W 10% owner · Insight Molecular Diagnostics Inc. | IMDX Insight Molecular Diagnostics Inc. | Other transactionFiling detailsSEC transaction code J Common Stock · Indirect ownership · See Footnote · Reported balance after transaction: 4401342 · Reflect shares of Insight Molecular Diagnostics Inc.'s (the "Issuer") common stock, no par value, purchased by the Reporting Person in an underwritten public offering of the Issuer at the public offering price of $1.75. · The shares of common stock reported herein are directly held by Patrick W Smith The Smith Irrevocable Trust U/A DTD 05/01/2015 (the "Trust"). As the trustee of the Trust, the Reporting Person may be deemed to beneficially own the securities held by the Trust. | 2026-11-17 | 2026-11-20 | 1,142,857 shares/units | SEC 4 | Follow |
Joint filing · 3 reporting ownersInsight Molecular Diagnostics Inc. | IMDX Insight Molecular Diagnostics Inc. | BuyFiling detailsSEC transaction code P Common Stock, no par value · Indirect ownership · Footnote · Reported balance after transaction: 16113455 · SEC code covers open-market or private transactions · The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. ("Broadwood Capital"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. | 2026-11-17 | 2026-11-19 | ≈ $0.00 0 shares/units | SEC 4 | From owner profile |
Joint filing · 3 reporting ownersInsight Molecular Diagnostics Inc. | IMDX Insight Molecular Diagnostics Inc. | BuyFiling detailsSEC transaction code P Common Stock, no par value · Direct ownership · Reported balance after transaction: 16113455 · SEC code covers open-market or private transactions · On November 17, 2026, Broadwood Partners purchased 3,428,571 shares of Common Stock, no par value (the "Common Shares"), of Insight Molecular Diagnostics Inc. (the "Issuer") from the Issuer in an underwritten public offering for a total purchase price of $5,999,999.25, or $1.75 per Common Share. · The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. ("Broadwood Capital"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. | 2026-11-17 | 2026-11-19 | ≈ $5,999,999.25 3,428,571 shares/units | SEC 4 | From owner profile |
Form 4 buy and sell codes cover open-market or private transactions. Form 13F shows quarterly reported holdings. Position changes can have causes other than trading. Disclosures are delayed and provided for research.